A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)

NCT01748877 Phase 2 COMPLETED

The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.

Details

Lead sponsor	NeurAxon Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	188
Start date	2013-01
Completion	2014-06

Conditions

• Post Herpetic Neuralgia

Interventions

• NXN-462
• Placebo

Primary outcomes

• Change from baseline to the last week of treatment in daily pain scores — 4 weeks
  Change from baseline to the last week of treatment in daily (24-hour recall) pain scores comparing NXN-462 with placebo

Countries

United States, Canada